Compare NCLH & VTAK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | NCLH | VTAK |
|---|---|---|
| Founded | 1966 | 2002 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Marine Transportation | Medical/Dental Instruments |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 8.4B | 3.0M |
| IPO Year | 2011 | 2018 |
| Metric | NCLH | VTAK |
|---|---|---|
| Price | $19.50 | $1.08 |
| Analyst Decision | Buy | |
| Analyst Count | 17 | 0 |
| Target Price | ★ $24.76 | N/A |
| AVG Volume (30 Days) | ★ 19.2M | 58.8K |
| Earning Date | 05-04-2026 | 08-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 89.53 |
| EPS | ★ 0.23 | N/A |
| Revenue | ★ $5,396,175,000.00 | $442,000.00 |
| Revenue This Year | $9.96 | $1,170.33 |
| Revenue Next Year | $6.60 | N/A |
| P/E Ratio | $82.87 | ★ N/A |
| Revenue Growth | 10.71 | ★ 3057.14 |
| 52 Week Low | $14.53 | $0.15 |
| 52 Week High | $27.18 | $4.31 |
| Indicator | NCLH | VTAK |
|---|---|---|
| Relative Strength Index (RSI) | 60.86 | 59.87 |
| Support Level | $17.66 | $0.77 |
| Resistance Level | $20.82 | $1.28 |
| Average True Range (ATR) | 0.83 | 0.09 |
| MACD | 0.24 | 0.02 |
| Stochastic Oscillator | 97.89 | 68.36 |
Norwegian Cruise Line is the world's third-largest publicly traded cruise company by berths (around 71,000). It operates 34 ships across three brands—Norwegian, Oceania, and Regent Seven Seas—offering both freestyle and luxury cruising. The company redeployed its entire fleet as of May 2022. With 17 passenger vessels on order among its brands through 2037, representing 46,000 incremental berths, Norwegian is increasing capacity faster than its peers, expanding its brand globally. Norwegian sails to around 700 global destinations.
Catheter Precision Inc is engaged in the design, manufacture, and sale of medical technologies focused in the field of cardiac electrophysiology, or EP. The company's two primary products include the VIVO System and LockeT. The VIVO System, which is an acronym for View into Ventricular Onset System(VIVO or VIVO System), is a non-invasive imaging system that offers 3D cardiac mapping to help with localizing the sites of origin of idiopathic ventricular arrhythmias in patients with structurally normal hearts prior to EP procedures. Its newest product, LockeT, is a suture retention device indicated for wound healing by distributing suture tension over a larger area in the patient in conjunction with a figure of eight suture closure.